Home/Pipeline/Cefiderocol (Fetroja®)

Cefiderocol (Fetroja®)

Gram-negative Bacterial Infections

MarketedCommercial

Key Facts

Indication

Gram-negative Bacterial Infections

Phase

Marketed

Status

Commercial

Company

Shionogi

About Shionogi

Shionogi is a premier, discovery-based Japanese pharmaceutical company with a 65+ year legacy in antibiotic innovation and a mission to supply the best possible medicine to protect patient health. The company has successfully diversified its pipeline beyond its core infectious disease expertise into antivirals, CNS disorders, and rare diseases, while maintaining a steadfast commitment to combating antimicrobial resistance (AMR). Its strategy combines deep in-house R&D capabilities with strategic global partnerships and licensing to accelerate development and commercialize novel therapeutics for serious unmet medical needs worldwide.

View full company profile

Therapeutic Areas

Infectious Diseases Central Nervous System (CNS)Rare Diseases Virology Oncology

Other Gram-negative Bacterial Infections Drugs

Drug	Company	Phase	Status
Inhaled Murepavadin (OMPTA)	Spexis	Phase 1	Active
OMPTA (LPS/BamA)	Spexis	Pre-clinical	Active
OMPTA (LptA Thanatin)	Spexis	Pre-clinical	Active
ABX-01	Centauri Therapeutics	Pre-clinical	Active
CTX-187	Centauri Therapeutics	Pre-clinical	Active